NEW YORK, NY--(Marketwired - June 12, 2014) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech firm. With preclinical studies set to begin any day now at Translational Drug Development (TD2), this is the first time the pancreatic cancer treatment that combines the live-cell encapsulation technology Cell-in-a-Box® with the anticancer drug ifosfamide will enter the clinic under the Nuvilex name.
These studies will have the company entering the clinic in an effort to treat symptoms related to pancreatic cancer, but could have it leaving the clinic with the potential to treat a host of abdominal cancers that include; liver cancer, stomach cancer, colorectal cancer, and kidney cancer among others.
Abdominal cancer is a general term for a variety of cancers, and it is a type of cancer that occurs when there is an uncontrolled growth of abnormal cells anywhere in the abdomen, the area between the lower chest and the groin. The abdomen consists of many organs, including the stomach, intestines, liver, gallbladder, pancreas, esophagus, and numerous blood vessels.
If the preclinical trials produce the results expected and can relieve the unbearable pain and slow the onset of ascites associated with advanced pancreatic cancer as well as other abdominal cancers, Nuvilex and its Cell-in-a-Box®/ifosfamide combination could find itself heading to Phase I-II clinical trials quickly with the potential of being added as part of a treatment regimen for a variety of abdominal cancers to relieve symptoms for close to a million new cancer cases every year.
The American Cancer Society estimates that in 2014 around 46,000 people will be diagnosed with pancreatic cancer in the US, but Nuvilex could find itself with a treatment that could help many more patients with the symptoms associated with other abdominal cancers.
Liver cancer, for instance, will be diagnosed in more than 700,000 new patients each year around the world. Liver cancer is a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year.
Meanwhile, the American Cancer Society estimates that 136,830 people will be diagnosed with colorectal cancer this year in the US alone, and 50,310 people in the country will die from the disease in 2014.
So, the work by TD2 in the clinic could very well prove that Nuvilex is headed for much bigger opportunities to treat deadly cancers. And, while this will be good news for shareholders, it's the best news for those patients looking for relief of the symptoms that are often seen as the reason many with these abdominal cancers give up.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Nuvilex content by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. SMMG has received total compensation of $97,685 for all created content related to Nuvilex. Additionally, a principal at SMMG currently owns 200,000 total shares of Nuvilex issued by the company through a consulting agreement which has since ended for work unrelated to content development. All shares have been held for the requisite period under Rule 144 as of April 30, 2014, and are eligible to be sold immediately without further notice. For more information: www.stockmarketmediagroup.com.